Thus, 10 of the 13 studies included define a positive outcome from anti-VEGF therapy as improvement in visual function (visual acuity), while three studies define it as an improvement in retinal morphology (resolution of macular edema). The gene discussed is VEGFA; the disease is macular retinal edema.